Chen Xiao-Feng, Wang Yumei, Ji Shaoxiu, Sun Xin, Feng Quansheng, Yu Han, Liu Chao
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Pharmacol. 2022 Jul 1;13:911250. doi: 10.3389/fphar.2022.911250. eCollection 2022.
Liver fibrosis is a leading contributor to chronic liver diseases such as cirrhosis and liver cancer, which pose a serious health threat worldwide, and there are no effective drugs to treat it. Qijia Rougan decoction was modified from , a traditional Chinese medicine (TCM) described in the "Wenyilun" manuscript. Qijia Rougan decoction possesses hepatoprotective and antifibrotic effects for clinical applications. However, its underlying mechanisms remain largely unknown. In this study, fibrotic rats induced by carbon tetrachloride (CCl) were treated with two doses of Qijia Rougan decoction. Histopathological and serum biochemical analyses were carried out to assess liver structure and function, respectively. High-performance liquid chromatography (HPLC) coupled with mass spectrometry (MS) was performed to identify bioactive compositions in Qijia Rougan decoction. Transcriptome analysis using mRNA-sequencing (mRNA-Seq) was used to explore the underlying mechanisms and verified by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting. Qijia Rougan decoction significantly attenuated CCl-induced hepatic fibrotic injury, supported by promoted liver function and improved liver fibrosis. Eight main representative components originating from raw materials in the Qijia Rougan decoction were found to possess an antifibrotic role. Mechanistically, Qijia Rougan decoction regulated biological processes such as oxidation-reduction, fatty acid metabolism, cell adhesion, and transforming growth factor beta (TGFβ) signaling. We determined that Qijia Rougan decoction reversed the expression of inflammatory cytokines and inhibited the activation of fibrosis-related TGFβ signaling. It also reversed the deterioration of liver structure and function in rats induced by CCl. Overall, Qijia Rougan decoction significantly mediated metabolism-associated processes, inhibited inflammatory reactions, and repressed fibrosis-related TGFβ signaling, which prevented liver fibrosis deterioration. Our study deepens our understanding of TCM in the diagnosis and treatment of liver fibrosis.
肝纤维化是导致肝硬化和肝癌等慢性肝病的主要因素,这些疾病在全球范围内对健康构成严重威胁,且目前尚无有效的治疗药物。芪甲柔肝汤是由《温疫论》中记载的一种中药化裁而来。芪甲柔肝汤在临床应用中具有保肝和抗纤维化作用。然而,其潜在机制在很大程度上仍不清楚。在本研究中,用两剂芪甲柔肝汤对四氯化碳(CCl)诱导的纤维化大鼠进行治疗。分别进行组织病理学和血清生化分析以评估肝脏结构和功能。采用高效液相色谱(HPLC)与质谱(MS)联用技术鉴定芪甲柔肝汤中的生物活性成分。利用mRNA测序(mRNA-Seq)进行转录组分析以探索潜在机制,并通过定量实时聚合酶链反应(qRT-PCR)和蛋白质免疫印迹法进行验证。芪甲柔肝汤显著减轻了CCl诱导的肝纤维化损伤,表现为肝功能得到改善,肝纤维化程度减轻。发现芪甲柔肝汤原料中的八种主要代表性成分具有抗纤维化作用。从机制上讲,芪甲柔肝汤调节氧化还原、脂肪酸代谢、细胞黏附以及转化生长因子β(TGFβ)信号传导等生物学过程。我们确定芪甲柔肝汤可逆转炎性细胞因子的表达并抑制纤维化相关的TGFβ信号传导的激活。它还逆转了CCl诱导的大鼠肝脏结构和功能的恶化。总体而言,芪甲柔肝汤显著介导了与代谢相关的过程,抑制了炎症反应,并抑制了与纤维化相关的TGFβ信号传导,从而防止了肝纤维化的恶化。我们的研究加深了我们对中医在肝纤维化诊断和治疗方面的理解。